Blood Clot clinical trials at University of California Health
2 research studies open to eligible people
open to eligible people ages up to 17 years
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
at UC Davis UCSF
United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
open to eligible people ages 3 months to 12 years
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Our lead scientists for Blood Clot research studies include Kristin Shimano.